Clinicians should: Assess baseline HbA1c and current glycemic control before discontinuation Implement or intensify alternative therapies (metformin, SGLT2 inhibitors, or other agents) before or concurrent with tirzepatide cessation Increase home glucose monitoring frequency for several weeks post-discontinuation Schedule follow-up to evaluate metabolic stability Special consideration for insulin or sulfonylurea users : Patients taking these medications alongside tirzepatide may need proactive dose adjustments when stopping tirzepatide to prevent hypoglycemia
If you only track one thing, make it protein
Genetics is a guide, not a guarantee
As blood pressure decreases with weight reduction, some patients may experience symptoms of relative hypotension, including dizziness, lightheadedness, or fatigue
do not shake vigorously Inspect solution Should be clear and colorless Label vial Date, concentration, batch number Refrigerate Store at 2-8C immediately Calculating Doses For research applications, accurate dose calculation is critical: Example Calculation: Cagrilintide 10mg vial Reconstituted with 2mL bacteriostatic water Concentration: 10mg 2mL = 5mg/mL For 0.6mg dose: 0.6mg 5mg/mL = 0.12mL (12 units on insulin syringe) For 1.2mg dose: 1.2mg 5mg/mL = 0.24mL (24 units on insulin syringe) For 2.4mg dose: 2.4mg 5mg/mL = 0.48mL (48 units on insulin syringe) Detailed guidance on peptide preparation and dosing can help ensure accurate research protocols
